Inflammatory Breast Cancer (IBC)

Inflammatory breast cancer (IBC) is a rare and highly aggressive subtype of breast cancer that poses significant clinical challenges. At Alfa Cytology, our team of experienced biologists work with you to develop IBC therapeutics.

Introduction to Inflammatory Breast Cancer (IBC)

Accounting for only 2-4% of all breast cancer cases, IBC is characterized by its rapid onset, propensity for locoregional recurrence, and dismal prognosis. Unlike its non-inflammatory counterparts, IBC often presents with distinct skin changes, such as erythema, edema, and peau d'orange appearance, which are the result of extensive dermal lymphatic invasion by tumor cells.

Fig.1 Update on systemic treatment for inflammatory breast cancer. (Chainitikun S., et al. 2020)

Therapy Development for Inflammatory Breast Cancer (IBC)

Emerging evidence suggests that the unique tumor microenvironment (TME) of IBC, characterized by extensive lymphovascular invasion, immune dysfunction, and aberrant angiogenesis, plays a pivotal role in driving aggressive disease progression.

Our preclinical studies have identified several promising molecular targets within the IBC TME, including components of the lymphangiogenic and angiogenic signaling cascades, as well as key immune checkpoint regulators.

Our Services

Inflammatory breast cancer is a relatively rare disease but malignant. Multiple factors influence prognosis and therapy options. Therefore, Alfa Cytology is working on providing one-stop solutions for inflammatory breast cancer, including but not limited to the following.

IBC Therapy Development Platforms

Modeling Services for IBC

At Alfa Cytology, we recognize the critical importance of robust preclinical models in the development of effective therapies for IBC. Given the unique biological features and aggressive nature of this disease, we have established a comprehensive suite of in vitro and in vivo modeling services to support our drug discovery and translational research efforts. 

Alfa Cytology is committed to the research and study of IBC, from molecular biology services, and cancer biomarker discovery services, to preclinical research services, providing one-stop services. Our cancer experts have many years of experience in the development of the latest therapies for IBC. If you are interested in our service, please contact us.